ELUT News & Events

Elutia announced that it granted equity awards on March 10, 2026 to three new employees as inducement awards under the Elutia Inc. 2026 Inducement Award Plan. The awards were approved by the independent Compensation Committee of the Board of Directors, and were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Under the Plan, the three new employees received an aggregate of 460,000 non-qualified stock options. The Options vest 25% on the first anniversary of the vesting commencement date, with the balance vesting in equal monthly installments over the following three years. Vesting is subject to each recipient's continued employment through the applicable vesting date. The Options have an exercise price of $1.09 per share, the closing price of Elutia's common stock on the Nasdaq Capital Market on March 10, 2026, the grant date. The Options are subject to the terms and conditions of the Plan and the applicable stock option agreement.

Elutia announced the appointment of Pete Ligotti as Chief Commercial Officer. Ligotti will lead the commercialization for NXT-41x.

"The success of EluPro was transformational for Elutia," said Dr. Randy Mills, Chief Executive Officer. "It validated the technical and commercial capability of our drug-eluting platform and enabled us to enter plastic and reconstructive surgery, where complication rates in breast reconstruction remain unacceptably high. We enter 2026 with a strong balance sheet and the capital required to develop and commercialize NXT-41x. With an experienced team and a focused strategy, we are positioned to execute and advance our mission so that patients can thrive without compromise."